CDC Advisory Panel Recommends Seniors to Receive RSV Vaccines

The Centers for Disease Control and Prevention’s (CDC) vaccination advisory panel recently voted to recommend the administration of vaccines for respiratory syncytial virus (RSV) to older adults, marking a significant development in the fight against the virus.

The CDC’s Advisory Committee on Immunization Practices (ACIP) decided in favor of recommending RSV vaccines for adults aged 65 and above.

Additionally, the committee voted to allow individuals between the ages of 60 and 64 to receive RSV vaccines with a “clinical decision making” approach. This means that they would consult their healthcare providers to determine if the vaccine is necessary for them.

During the meeting, the RSV vaccines manufactured by Pfizer and GlaxoSmithKline (GSK) were under consideration. These vaccines have already obtained approval from the Food and Drug Administration (FDA) for use in older adults to prevent RSV infections.

Data presented during the meeting revealed that the RSV vaccines offer robust protection of over 80 percent. Both vaccines are administered in single doses, and the studies presented by the companies indicate that they can be safely given alongside common flu vaccines.

These RSV vaccines represent a significant breakthrough as they are the first of their kind to be made available. While most non-immunocompromised adults can recover from RSV infections with rest and self-care, the availability of vaccines provides an added layer of protection.

GSK representatives disclosed that their RSV vaccine will be priced between $200 and $295, while Pfizer provided a price range of $180 to $270 for their vaccine. It’s important to note that Pfizer’s range is subject to change due to ongoing price negotiations.

RSV is a common virus that typically manifests as flu-like symptoms. However, young infants and older adults can develop severe cases. In 2022, the U.S. experienced a surge in RSV cases among infants who had not previously been exposed to the virus.

Most children are exposed to RSV, often referred to as a “day care disease,” before the age of 2.

Last year’s increase in RSV cases drew attention to the lack of preventive and treatment options available. Recently, FDA advisory panels also recommended RSV vaccines and treatments for young infants.

Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.